TG-Rich Lipoproteins

Very low-density lipoprotein (VLDL) and chylomicrons, which are known as TG-rich lipoproteins (TRLs), are spherical particles with core lipids (TG and cholesterol esters), phospholipids, free cholesterol, and surface apolipoproteins. The origins of TGs are generally exogenous or endogenous. Exogenous TG is mostly obtained from daily diet and transported within chylomicrons, while endogenous TG circulates in VLDL and is mostly formed in the hepatobiliary system.

1. Introduction

During the past decades, the risk of atherosclerotic cardiovascular disease (ASCVD) and mortality has been much reduced due to advances in pharmacotherapy, intervention devices, and techniques. [1][2] ASCVD risk is significantly reduced by controlling blood low-density lipoprotein cholesterol (LDL-C) level [3]. Statin is the drug of choice to treat hypercholesterolemia. Non-statin medication including PCSK9 inhibitors and ezetimibe would further reduce LDL-C level while added to a statin or act as statin alternatives. Bempedoic acid is a newly approved effective non-statin LDL-C lowering agent [4]. Bempedoic acid has been associated with increased incidence of hyperuricemia, gout, and elevated serum creatinine level. On-going trials will clarify its long-term effect on cardiovascular outcomes [5].

However, the risk of ASCVD has not been eliminated. In the CANTOS trial, patients with a history of myocardial infarction (MI) had a 20% 5-year rate of recurrent major cardiovascular events (MACEs) despite statin treatment [6]. These residual risks can be caused by many factors, and methods to modify these factors have been proposed in contemporary guidelines. For example, measuring the lipoprotein(a) (Lp(a)) level should be considered among high-risk patients for a more precise reclassification and identification [3][7]. Lipid and lipoprotein metabolism disorders remain an unsolved problem. Whilst most guidelines encourage achieving target levels of specific lipoproteins to reduce the risk of ASCVD, increasing evidence has shown that molecular modification of these lipoproteins also has a critical impact on their atherogenecity and may contribute to residual ASCVD risk (**Figure 1**). For example, native low-density lipoproteins (LDLs) are much less atherogenic than those that have been structurally modified, such as by oxidation [8]. Apolipoproteins also play important roles in modulating lipid homeostasis and may alter the functions of different lipoproteins. In this review, we aim to update the evidence on modifications of major lipid components, including LDL, high-density lipoprotein (HDL), triglycerides (TGs), apolipoprotein, and Lp(a). We also discuss examples of translating findings from basic research to potential therapeutic targets for drug development.

Figure 1. Schematic diagram showing the essential modifications of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) and potential therapeutic targets. HDL promotes cholesterol efflux from cells within atherosclerotic plaques through reverse cholesterol transport (RCT) and transports excess cholesterol from peripheral tissues to the liver for excretion. Post-translational modifications including oxidation, carbamylation, glycation, and alterations of its lipidomic and proteomic structure result in dysfunctional HDL. Infusion of reconstituted apolipoprotein A-I, CSL112, enhances RCT. Lipoprotein(a) (Lp(a)) promotes atherosclerosis through its proinflammatory and antifibrinolytic effects. The production of Lp(a) in the liver can be reduced by the novel antisense oligonucleotide, PELACARSEN. Angiopoietin-like protein 3 (ANGPTL3) produced in the liver inhibits lipoprotein lipase (LPL)-induced lipolysis, resulting in increased circulating triglycerides carried by triglyceride-rich lipoproteins (TRLs), and accelerated atherosclerosis [9]. This process can be blocked by the ANGPTL3 inhibitor, evinacumab. Native LDL is modified by oxidation, glycation, peroxidation, and apolipoprotein C-III (apoC-III) adhesion and becomes more atherogenic. The expression of apoC-III can be suppressed by another novel antisense oligonucleotide, AKCEA-ApoCIII-LRx.

2. Triglycerides

Hypertriglyceridemia is a prevalent condition observed in daily medical care. According to previous literature, its prevalence in the adult population is approximately 10% [10][11][12]. Moreover, the increasing trend of hypertriglyceridemia has been parallel to that of type 2 diabetes and obesity in the past decades [11]. Very low-density lipoprotein (VLDL) and chylomicrons, which are known as TG-rich lipoproteins (TRLs), are spherical particles with core lipids (TG and cholesterol esters), phospholipids, free cholesterol, and surface apolipoproteins. The origins of TGs are generally exogenous or endogenous. Exogenous TG is mostly obtained from daily diet and transported within chylomicrons, while endogenous TG circulates in VLDL and is mostly formed in the hepatobiliary system.

The levels of fasting and postprandial TGs depend on the balance between lipoprotein lipase-mediated lipolysis and uptake in the human liver. VLDL overproduction is the most common upstream cause of hypertriglyceridemia, and the inherited capacity of the lipoprotein lipase-mediated lipolysis pathway modulates the steady-state level. Comprehensive evaluations are strongly suggested when hypertriglyceridemia is suspected. Furthermore, insulin resistance, overweight, and type 2 diabetes mellitus may be detected simultaneously in this population. In clinical practice, these conditions are usually treated as metabolic syndrome, which comprises the aforementioned three conditions. Metabolic syndrome may increase VLDL levels, especially when free acids and insulin accumulate in the circulation [13]. An environment with an extremely high free acid concentration, hyperglycemia, and insulin resistance, would result in increased chylomicron secretion, while glucagon-like peptide 1 would play a counterbalancing role in the pathway [13]. Moreover, apoC-III has been shown to decrease the removal of remnants in individuals with high VLDL levels and a higher apoC-III concentration is an important factor leading to dyslipidemia [14].

TG-rich VLDL particles and metabolic remnants are the main transporters of TGs in human circulation. The plasma concentration of TGs has been shown to be parallel to the circulating apo B-containing TRL level, which is known to be associated with ASCVD formation [15]. A non-fasting TG level of 6.6 mmol/L was significantly associated with a 5-fold higher risk of acute coronary syndrome, a 3-fold increased risk of stroke, and a 2-fold increased adjusted risk of all-cause mortality compared to a level of 0.8 mmol/L in population-based cohort studies in Copenhagen [16][17]. These results show the importance of monitoring the TG level in primary ASCVD risk modification. In another study investigating secondary ASCVD risk after acute MI, TGs were found to be significantly associated with both short-term and long-term ASCVD outcomes. Furthermore, most patients in the study had been treated with statins, which further highlights the crucial role of TGs in secondary ASCVD prevention [18].

Several studies have used Mendelian randomization and shown that the association between TG concentrations and ASCVD may be causal. Nevertheless, the evidence needs to be interpreted with caution, because nearly all variants associated with TGs were also associated with the trends of HDL-C, LDL-C, and Lp(a) [19][20]. In another study, the authors used Mendelian randomization to show that TG-lowering lipoprotein lipase variants and LDL-C-lowering LDL receptor variants had similar effects on the ASCVD risk per unit change in apo-B [21]. Taken together, these studies demonstrated the causality of TRLs and their remnants on the ASCVD risk, partly due to the plasma level of apo B-containing particles. Another possible mechanism underlying the relationship between TGs and atherosclerosis is the deposition of cholesterol-ester-enriched smaller TRLs on the arterial walls and the subsequent initiation of pro-inflammatory/thrombotic pathways. Furthermore, high circulating TG levels have been associated with pathological HDL-C particles, which could lead to an increased risk of ASCVD [12]. In contrast, the correlation between circulating TG concentrations and ASCVD risk has varied among previous studies and was lost in several multivariate analyses [22]. Moreover, the correlation was reduced after adjusting for non-HDL-C or apoB in an epidemiological study [23].

Collectively, the aforementioned studies demonstrate that TRLs and their remnants play a crucial role in ASCVD risk assessment [24]. According to current clinical guidelines, lowering LDL-C remains the primary treatment goal in the management of dyslipidemia. In addition, clinicians should focus on modifications of TRLs, such as non-HDL-C and apoB, which are highly recommended in the updated guideline [7]. Previous studies on fibrates, niacin, and cholesteryl ester transfer protein inhibitors did not demonstrate a robust or convincing reduction in the risk of ASCVD in an optimal cholesterol-lowering population [25][26]. Nevertheless, several ongoing trials are focusing on the important roles of TRL with

respect to the residual ASCVD risk in statin users. The results of these ongoing clinical trials and upcoming evidence regarding omega-3 fatty acids (high-dose icosapent ethyl) [21], and the selective peroxisome proliferator-activated receptor modulator pemafibrate may help to clarify which population will benefit from a reduced risk of ASCVD by lowering TRL levels [27][28]. The development of molecular technologies has provided more detailed information on the pathways underlying TRL modulation. Several emerging therapeutic molecules have been targeted, including inhibitors of angiopoietin-like protein 3 (evinacumab; allele-specific oligonucleotide IONISANGPTL3-LRx) (**Table 1**) [29], and inhibitors of intestinal diacylglycerol acyltransferase (pradigastat) [30], as well as those targeting apoC-II and A-V and angiopoietin-like protein 4 [31]. TRL modification strategies in specific patients can be expected to become a crucial part of lipid-directed treatment in the near future.

Table 1. Potential therapeutic targets and emerging pharmacological lipid-lowering approaches.

Potential Therapeutic Target	Pharmacological Approach	Published Clinical Trials	Subjects	Pros	Cons	Ongoing Trials and Aims of The Trials
Angiopoietin-like protein 3	**Evinacumab, a recombinant human monoclonal antibody that inhibits angiopoietin-like protein 3**	**ELIPSE HoFH (phase 3)** [32]	**Patients with homozygous familial hypercholesterolemia**	• 47.1% reduction in LDL-C levels • Evident LDL-C reduction occurred early after treatment • Approval on 11 February 2021 in the USA for use as an adjunct to other LDL-C lowering therapies for the treatment of adult and paediatric patients aged 12 years and older with homozygous familial hypercholesterolemia	• Influenza-like illness, pain in extremity, asthenia, constipation, abdominal pain, anaphylaxis • High costs, annual cost of the drug estimated to be USD 450,000 on average [33].	• NCT0340974417 evaluate the lor term safety and efficacy of Evinacumab in patients with homozygous fa hypercholesterc • NCT042339187 evaluate the eff and safety of Evinacumab in pediatric patien with homozygo familial hypercholesterc

Potential Therapeutic Target	Pharmacological Approach	Published Clinical Trials	Subjects	Pros	Cons	Ongoing Trials and Aims of The Trials
ApoC-III	Volanesorsen, a 2′-O-(2-methoxyethyl)-modified antisense oligonucleotide	APPROACH (phase 3) [34]	Patients with familial chylomicronemia syndrome	• 77% decrease in mean TG levels.	• 25 (76%) in the volanesorsen group had platelet-level decreases to below 140,000 per microliter • Decreases in platelet levels were reversible with an interruption in dosing	
		COMPASS (phase 3) [35]	Patients with severe hypertriglyceridemia	• 73% decrease in TG levels.		
	AKCEA-ApoCIII-LRx, a GalNAc$_3$ modified antisense oligonucleotide	Phase 1/2a trial [36]	Healthy volunteers	• Dose-dependent reductions of TG levels from -12% to -77% • No significant effects on the liver or kidney function and no thrombocytopenia events occurred.		• NCT0338523 evaluate the eff AKCEA-APOCI on TG levels in patients with hypertriglycerid and established cardiovascular disease • NCT0456843 evaluate the eff AKCEA-APOCI on TG levels in patients with fa chylomicronem syndrome
ApoA-I	CSL112, a plasma-derived reconstituted apoA-I	Phase 2b AEGIS-I trial [37]	Patients with myocardial infarction	• A 4.3-fold increase in ABCA1-dependent cholesterol efflux capacity and a 2.45-fold increase in ApoA-I level. • No significant change in liver or kidney function		• NCT0347322 investigate the of CSL112 on r cardiovascular in subjects with coronary syndr (AEGIS-II)
Apolipoprotein(a)	PELACARSEN, an GalNAC$_3$ modified antisense oligonucleotide	Phase 2 trial [38]	Patients with established ASCVD	• 80% reduction in Lp(a) level • Up to 88% decrease in oxidized phospholipids • No significant change in platelet count, liver function, and renal function		• NCT0402355 assess the imp Lp(a) lowering PELACARSEN major cardiovas events in patier with cardiovasc disease (Lp(a)HORIZOI

ABCA1, ATP binding cassette subfamily A member 1, ASCVD, atherosclerotic cardiovascular disease; GalNAc$_3$, triantennary N-acetyl galactosamine; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; Lp(a), lipoprotein(a).

3. Conclusions

LDL may undergo structural change by oxidation, glycation, and peroxidation, and these modifications result in progressive atherosclerosis. HDL may undergo post-translational modifications such as oxidation, carbamylation, and glycation, and alteration of its cargo molecules such as SAA, LCAT, apoM, S1P, and PON1.

These modifications could decrease the atheroprotective function of HDL. Currently, no pharmacological approach has been developed to block or reverse these modifications. Research on how these modifications are modulated is still needed and will uncover more potential therapeutic targets. Pharmacotherapies targeting a reduction in TGs, apoC-III, and Lp(a), and an increase in apoA-1, are currently under investigation, and promising preliminary results have been reported. Clinical trials that assess the effects of these therapies on cardiovascular events are underway. These targets may further shape the landscape of dyslipidemia treatment and decrease the residual risk of cardiovascular events.

References

1. Mensah, G.A.; Wei, G.S.; Sorlie, P.D.; Fine, L.J.; Rosenberg, Y.; Kaufmann, P.G.; Mussolino, M.E.; Hsu, L.; Addou, E.; Engelgau, M.M.; et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ. Res. 2017, 120, 366–380.

2. Amini, M.; Zayeri, F.; Salehi, M. Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: Results from global burden of disease study 2017. BMC Public Health 2021, 21, 1–12.

3. Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; De Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guideline. Circulation 2019, 139, e1082–e1143.

4. Banach, M.; Duell, P.B.; Gotto, A.M., Jr.; Laufs, U.; Leiter, L.A.; Mancini, G.B.J.; Ray, K.K.; Flaim, J.; Ye, Z.; Catapano, A.L. Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia. JAMA Cardiol. 2020, 5, 1124–1135.

5. Cicero, A.F.G.; Pontremoli, R.; Fogacci, F.; Viazzi, F.; Borghi, C. Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies. Drug Saf. 2020, 43, 727–736.

6. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131.

7. Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J. 2020, 41, 111–188.

8. Yoshida, H.; Kisugi, R. Mechanisms of LDL oxidation. Clin. Chim. Acta 2010, 411, 1875–1882.

9. Ruscica, M.; Macchi, C.; Fogacci, F.; Ferri, N.; Grandi, E.; Rizzoli, E.; D'Addato, S.; Borghi, C.; Cicero, A.F. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. Eur. J. Prev. Cardiol. 2020, 27, 2251–2254.

10. Dron, J.S.; Wang, J.; Cao, H.; McIntyre, A.D.; Iacocca, M.A.; Menard, J.R.; Movsesyan, I.; Malloy, M.J.; Pullinger, C.R.; Kane, J.P.; et al. Severe hypertriglyceridemia is primarily polygenic. J. Clin. Lipidol. 2019, 13, 80–88.

11. Truthmann, J.; Schienkiewitz, A.; Busch, M.A.; Mensink, G.B.M.; Du, Y.; Bosy-Westphal, A.; Knopf, H.; Scheidt-Nave, C. Changes in mean serum lipids among adults in Germany: Results from National Health Surveys 1997-99 and 2008-11. BMC Public Health 2016, 16, 240.

12. Hegele, R.A.; Ginsberg, H.N.; Chapman, M.J.; Nordestgaard, B.G.; Kuivenhoven, J.A.; Averna, M.; Borén, J.; Bruckert, E.; Catapano, A.L.; Descamps, O.S.; et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014, 2, 655–666.

13. Xiao, C.; Dash, S.; Morgantini, C.; Hegele, R.A.; Lewis, G.F. Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes 2016, 65, 1767–1778.

14. Stahel, P.; Xiao, C.; Hegele, R.A.; Lewis, G.F. The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. Can. J. Cardiol. 2018, 34, 595–604.

15. Ganda, O.P.; Bhatt, D.L.; Mason, R.P.; Miller, M.; Boden, W.E. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J. Am. Coll. Cardiol. 2018, 72, 330–343.

16. Nordestgaard, B.G.; Varbo, A. Triglycerides and cardiovascular disease. Lancet 2014, 384, 626–635.

17. Madsen, C.M.; Varbo, A.; Nordestgaard, B.G. Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: A contemporary population-based study. Eur. Heart J. 2018, 39, 610–619.

18. Schwartz, G.G.; Abt, M.; Bao, W.; DeMicco, D.; Kallend, D.; Miller, M.; Mundl, H.; Olsson, A.G. Fasting Triglycerides Predict Recurrent Ischemic Events in Patients with Acute Coronary Syndrome Treated with Statins. J. Am. Coll. Cardiol. 2015, 65, 2267–2275.

19. Sarwar, N.; Sandhu, M.S.; Ricketts, S.L.; Butterworth, A.S.; Di Angelantonio, E.; Boekholdt, M.; Ouwehand, W.; Watkins, H.; Samani, N.J.; Saleheen, D.; et al. Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies. Lancet 2010, 375, 1634–1639.

20. Dron, J.S.; Hegele, R.A. Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr. Opin. Lipidol. 2017, 28, 161–169.

21. Ference, B.A.; Kastelein, J.J.P.; Ray, K.K.; Ginsberg, H.N.; Chapman, M.J.; Packard, C.J.; Laufs, U.; Oliver-Williams, C.; Wood, A.M.; Butterworth, A.S.; et al. Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants with Risk of Coronary Heart Disease. JAMA 2019, 321, 364–373.

22. Sarwar, N.; Danesh, J.; Eiriksdottir, G.; Sigurdsson, G.; Wareham, N.; Bingham, S.; Boekholdt, S.M.; Khaw, K.-T.; Gudnason, V. Triglycerides and the Risk of Coronary Heart Disease. Circulation 2007, 115, 450–458.

23. Di Angelantonio, E.; Gao, P.; Pennells, L.; Kaptoge, S.; Caslake, M.J.; Thompson, A.; Butterworth, A.S.; Sarwar, N.; Wormser, D.; Saleheen, D.; et al. Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA 2012, 307, 2499–2506.

24. Laufs, U.; Parhofer, K.G.; Ginsberg, H.N.; Hegele, R.A. Clinical review on triglycerides. Eur. Heart J. 2020, 41, 99–109c.

25. Willer, C.J.; Schmidt, E.M.; Sengupta, S.; Peloso, G.M.; Gustafsson, S.; Kanoni, S.; Ganna, A.; Chen, J.; Buchkovich, M.L.; Mora, S.; et al. Discovery and refinement of loci associated with lipid levels: A Systematic Review and Meta-analysis. Nat. Genet. 2013, 45, 1274–1283.

26. Silverman, M.G.; Ference, B.A.; Im, K.; Wiviott, S.D.; Giugliano, R.P.; Grundy, S.M.; Braunwald, E.; Sabatine, M.S. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA 2016, 316, 1289–1297.

27. Ference, B.A.; Yoo, W.; Alesh, I.; Mahajan, N.; Mirowska, K.K.; Mewada, A.; Kahn, J.; Afonso, L.; Williams, K.A.; Flack, J.M. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease: A Mendelian Randomization Analysis. J. Am. Coll. Cardiol. 2012, 60, 2631–2639.

28. Holmes, M.V.; Asselbergs, F.W.; Palmer, T.M.; Drenos, F.; Lanktree, M.B.; Nelson, C.P.; Dale, C.E.; Padmanabhan, S.; Finan, C.; Swerdlow, D.I.; et al. Mendelian randomization of blood lipids for coronary heart disease. Eur. Heart J. 2015, 36, 539–550.

29. Razi, F.; Forouzanfar, K.; Bandarian, F.; Nasli-Esfahani, E. LDL-cholesterol measurement in diabetic type 2 patients: A comparison between direct assay and popular equations. J. Diabetes Metab. Disord. 2017, 16, 43.

30. Langlois, M.R.; Descamps, O.S.; van der Laarse, A.; Weykamp, C.; Baum, H.; Pulkki, K.; von Eckardstein, A.; De Bacquer, D.; Borén, J.; Wiklund, O.; et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis 2014, 233, 83–90.

31. Baca, A.M.; Warnick, G.R. Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B. Clin. Chem. 2008, 54, 907–910.

32. Raal, F.J.; Rosenson, R.S.; Reeskamp, L.F.; Hovingh, G.K.; Kastelein, J.J.P.; Rubba, P.; Ali, S.; Banerjee, P.; Chan, K.-C.; Gipe, D.A.; et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N. Engl. J. Med. 2020, 383, 711–720.

33. Kuehn, B.M. Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia with a Hefty Price Tag. Circulation 2021, 143, 2494–2496.

34. Witztum, J.L.; Gaudet, D.; Freedman, S.D.; Alexander, V.J.; Digenio, A.; Williams, K.R.; Yang, Q.; Hughes, S.G.; Geary, R.S.; Arca, M.; et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N. Engl. J. Med. 2019, 381, 531–542.

35. Gouni-Berthold, I.; Alexander, V.J.; Yang, Q.; Hurh, E.; Steinhagen-Thiessen, E.; Moriarty, P.M.; Hughes, S.G.; Gaudet, D.; Hegele, R.A.; O'Dea, L.S.L.; et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021, 9, 264–275.

36. Alexander, V.J.; Xia, S.; Hurh, E.; Hughes, S.G.; O'Dea, L.; Geary, R.S.; Witztum, J.L.; Tsimikas, S. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur. Heart J. 2019, 40, 2785–2796.

37. Michael Gibson, C.; Korjian, S.; Tricoci, P.; Daaboul, Y.; Yee, M.; Jain, P.; Alexander, J.H.; Steg, P.G.; Lincoff, A.M.; Kastelein, J.J.; et al. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation 2016, 134, 1918–1930.

38. Tsimikas, S.; Karwatowska-Prokopczuk, E.; Gouni-Berthold, I.; Tardif, J.-C.; Baum, S.; Steinhagen-Thiessen, E.; Shapiro, M.D.; Stroes, E.S.; Moriarty, P.M.; Nordestgaard, B.G.; et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N. Engl. J. Med. 2020, 382, 244–255.